Rossari Biotech reported a slight increase in its net profit for the fourth quarter of FY25, which rose to Rs 34.44 crore, up from Rs 34.13 crore in the same period last year.
The company’s revenue from operations grew by 22.6%, reaching Rs 579.56 crore in Q4 FY25, compared to Rs 472.72 crore in Q4 FY24.
Profit before tax (PBT) for the quarter was Rs 47.71 crore, which is a 4.7% increase from Rs 45.57 crore recorded in Q4 FY24. However, the company’s total expenses for the quarter went up by 24.8%, reaching Rs 533.79 crore. Key expenses included the cost of materials consumed, which rose by 21.65% to Rs 369.77 crore, employee costs, which grew by 41.7% to Rs 35.48 crore, and finance costs, which surged by 118.3% to Rs 5.5 crore.
The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) dropped by 9.27%, falling to Rs 69.5 crore compared to Rs 63.6 crore in the same quarter last year. As a result, the EBITDA margin also decreased to 12% from 13.5% in Q4 FY24.
Read More:Â Tejas Networks Shares Drop 9.51% to Rs 778.10 After Reporting Q4 FY25 Loss of Rs 71.80 Crore
On a yearly basis, Rossari Biotech’s consolidated net profit for FY25 increased by 4.35% to Rs 136.38 crore, while its revenue rose by 13.64% to Rs 2,080.29 crore, compared to the previous financial year.
The company’s promoters, Edward Menezes (Executive Chairman) and Sunil Chari (Managing Director), commented that they ended the year with stable performance despite a challenging business environment. The growth was mainly driven by strong export performance and solid demand across major business areas like agrochemicals, personal care, and consumer goods. They also highlighted that their investments in global partnerships were proving successful, particularly in emerging markets like institutional cleaning and direct-to-consumer (B2C) businesses.
Rossari Biotech plans to continue investing in expanding its capacity to support future growth. The company announced an additional Rs 97 crore in capital expenditure (capex) for its subsidiaries, Unitop Chemicals and Tristar Intermediates, as well as Rs 95 crore for Rossari Biotech itself. These projects, expected to be completed by Q4 FY26, aim to enhance operational efficiency and ensure a reliable supply of products. The company also mentioned that other ongoing expansion projects are progressing well.
Looking ahead, the company remains focused on achieving sustainable, profitable growth through strong execution, innovation, and strategic expansion. They are optimistic about maintaining growth, supported by a strong financial position, adaptable business model, and an expanding global presence.
Also Read: Experts Reveal Why Palm Oil Prices Are Plummeting—Find Out More!
In other news, Rossari Biotech’s board of directors has declared a final dividend of Rs 0.50 per share for FY25, which will be paid to shareholders within 10 working days of the Annual General Meeting, subject to approval by the company’s members.
Rossari Biotech, a manufacturer of specialty chemicals, offers customized solutions in areas like home and personal care products, textile chemicals, and animal health and nutrition.
Despite the positive results, the company’s stock price dropped by 0.79% to Rs 693.25 on the Bombay Stock Exchange (BSE).
